http://orcid.org/0000-0002-4902-4383
References
- Statistics Canada. Table 1020551. Deaths and mortality rate, by selected grouped causes, age group and sex, Canada annual, 2016. Available at: http://www5.statcan.gc.ca/cansim/a47 [Last accessed 21 January 2016]
- Public Health Agency of Canada. Economic burden of illness in Canada (2005–2008), 2014. Available at: http://www.phac-aspc.gc.ca/publicat/ebic-femc/2005-2008/index-eng.php [Last accessed 10 January 2016]
- Asghari S, Aref-Eshghi E, Godwin M, et al. Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. BMJ Open 2015;5:e007954
- Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67
- LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6
- Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet (London, England) 2013;381:40-6
- Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015;36:1186-94
- Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49-S73
- SCORE Systematic Cerebrovascular and Coronary Risk Evaluation Canada. Methods on how to use the score table, 2011. Available at: http://www.score-canada.ca/en/profesionnal/method [Last accessed 1 March 2016]
- D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53
- ClinCalc. Evidence-based clinical decision support tools and calculators for medical professionals, 2016. Available at: http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx [Last accessed 1 March 2016]
- Cupples LA, D’Agostino RB. Section 34: some risk factors related to the annual incidence of ardiovascular disease and death in pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, eds. Framingham Heart Study: 30 Year Follow-Up. Bethesda, MD: US Department of Health and Human Services, 1987
- Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
- Europe Society of Cardiology. SCORE Risk Charts. The European cardiovascular disease risk assessment model. Available at: http://www.escardio.org/Guidelines-&-Education/Practice-tools/CVD-prevention-toolbox/SCORE-Risk-Charts [Last accessed 20 March 2016]
- Thompson A, Temple NJ. The case for statins: has it really been made? J Roy Soc Med 2004;97
- Pencina MJ, D’Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009;119:3078-84